Merz Aesthetics Launches New Belotero® Lips Dermal Filler Products
Merz, a global leader in medical aesthetics, today announced the launch of Belotero® Lips, with products specifically designed for lip enhancement and treatment of perioral lines. The line includes two hyaluronic acid (HA) dermal filler products that complement each other to deliver safe, effective and natural-looking cosmetic results.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180409005702/en/
Belotero Lips Shape and Contour (Graphic: Business Wire)
Popularized by celebrities and social media influencers, the lip-filler market for female millennials is on the fast track to growth: lip beautification with hyaluronic acid fillers is currently among the most frequently requested procedures in aesthetic practices1. Designed to appeal to a broader and more youthful target audience, the new Belotero® Lips campaign emphasizes the importance of individual beauty and emotions with the tagline “Showing off not just you - but an enhanced version of you.” Most importantly, Belotero® Lips gives aesthetic physicians more creative power with two new products that can be tailored to meet every individual patient's needs and desires.
“A single product is often not versatile enough to deliver the natural, personalized result desired by lip patients,” said Dr. Yannick Grosskreutz, Vice President and Head of Global Marketing for Merz. “With the launch of Belotero® Lips Shape and Contour, Merz is proud to now offer physicians a unique complementary approach to lip enhancement.”
Modern female consumers already know what it means to “get their lips done.” As a result they have high expectations: results need to be natural, long-lasting and comfortable, and lip treatment is seen as a way to show off their own enhanced yet unique beauty. Just as lipstick and lipliner complement each other, Belotero® Lips Shape and Belotero® Lips Contour provide volume and definition for patient-specific, optimized results. Belotero® Lips Shape is intended for lip augmentation and enhancing the upper and lower lip, while Belotero® Lips Contour is designed to define the outline of the lip.
“Full, well-defined lips are a key signature of youth and beauty. That is why in my practice, I often see patients looking to enhance their smile and to address the signs of aging in this crucial area of the face,” said Dr. Uliana Gout, Cosmetic Doctor and Founder of London Aesthetic Medicine, UK. “Belotero® Lips is positioned for good tissue integration, delivery of high patient satisfaction and natural-looking results for all ages. Due to the extra versatility offered by the Belotero® Lips concept, with products specifically designed for both shaping and contouring, this allows for a tailored lip treatment for our patients.”
Lip augmentation using Belotero® Lips Shape and Belotero® Lips Contour was clinically assessed in a retrospective, multicenter study involving 146 patients.2 Observation period took place over 4 months, with assessment of handling and treatment results. For CPM-HAL2, the outcome with regard to naturalness and evenness after 2 weeks was assessed by the vast majority as very good (87%). This very good assessment was still maintained for 66.7% of patients after 4 months. The most common side effects observed following lip treatment with Belotero® were: swelling, tenderness, bruising, pain and redness. The majority of these side effects were mild and have also been observed in other lip enhancement clinical trials. Belotero® Lips Shape and Belotero® Lips Contour should only be administered by a physician or qualified healthcare professional.
Belotero® Lips products are now available in select countries in Europe, with additional markets to be added later this year. For more details, please visit https://global.belotero.com/ or follow @Merz_Aesthetics on Instagram.
About Merz
With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned medical aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, solid financial strength and continuous growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.
1 Sarnoff DS, Gotkin RH. Six steps to the “perfect” lip. J Drugs Dermatol. 2012 Sep;11(9):1081-8.
2 Fischer TC, et al. Hyaluron Filler Containing Lidocaine on a CPM Basis for Lip Augmentation: Reports from Practical Experience. Facial Plast Surg. 2016 Jun;32(3):283-8.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180409005702/en/
Contact information
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana
Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 20:23:00 EEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 19:19:00 EEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
Armis Named a Leader in IoT Security Solutions, Q3 2025 Evaluation3.9.2025 16:58:00 EEST | Press release
Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025. This achievement comes on the heels of Armis being named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest scores possible in 9 key criteria. According to the report, “Armis’ vision centers on delivering enterprise-wide exposure management that goes beyond IoT and OT devices. Its innovation investments and acquisitions support this goal. Its roadmap aligns with customer priorities while anticipating future needs to ensure the platform evolves alongside its clients. This forward-looking strategy fosters successful adoption and helps customers deploy the Centrix platform successfully.” “We’re proud to once again be recognized by Forrester as a leader and specifically highlighted by customers for our overall effectivenes
Rapid Medical™ Surpasses 1,000 Cases With DRIVEWIRE™ 24 in North America and Expands Into Europe With MDR Approval3.9.2025 16:46:00 EEST | Press release
Rapid Medical™, a leading developer of active endovascular devices, announces that its DRIVEWIRE™ 24 steerable guidewire has been used in more than 1,000 neurovascular procedures in North America during a limited commercial launch beginning earlier this year. The company also announced receipt of CE Mark under the European Medical Device Regulation (MDR), as presented at the 2025 ESMINT Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903530140/en/ “In my experience, the wire provides a unique combination of precision and support that simply hasn’t been possible with conventional technologies,” stated Dr. Erez Nossek, a neurosurgeon at NYU Langone in New York, NY. “It has become a reliable tool that allows us to approach any anatomy with greater efficiency and less time.” As the first steerable 0.024” guidewire, DRIVEWIRE has quickly become a go-to technology in ischemic stroke, aneurysms, and other complex
Andersen Consulting Strengthens End-to-End Technology Capabilities Through Collaboration with FirstQA Systems3.9.2025 16:30:00 EEST | Press release
Andersen Consulting adds depth to its digital transformation and AI capabilities through a Collaboration Agreement with FirstQA Systems, a leading technology services provider known for its expertise in business AI, digital transformation, and cybersecurity. Headquartered in Japan since 2011, FirstQA Systems K.K. is a consulting-led technology services firm supporting Fortune 500 companies and multinational enterprises across Asia, Europe, and North America. The firm specializes in AI, digital transformation (leveraging ServiceNow, SAP, and Salesforce platforms), and IT and OT cybersecurity. Through its group company, Himitsu Lab Limited, FirstQA Systems delivers next-generation Agentic AI solutions powered by the HIMITSU8™ Unified Development Framework (UDF)™. The company’s industry expertise spans manufacturing, pharmaceuticals, and banking and financial services. "Our collaboration with Andersen Consulting represents an exciting step forward for enterprise transformation," said Nave
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom